)
Sohini Das writes on automobile and healthcare sectors for Business Standard. Over her 17 years as a journalist, she has covered multiple sectors and issues -- FMCG, dairy, tourism, and state elections, among others, across Kolkata, Ahmedabad, and Mumbai. She loves doing personality stories and ground reportage.
Sohini Das writes on automobile and healthcare sectors for Business Standard. Over her 17 years as a journalist, she has covered multiple sectors and issues -- FMCG, dairy, tourism, and state elections, among others, across Kolkata, Ahmedabad, and Mumbai. She loves doing personality stories and ground reportage.
ZyCoV-D can remain stable at 25 degrees Celsius for months
The genome of the UK-variant has 17 mutations, eight of those were in the spike protein domain
To raise manufacturing capacity by 30% over next 2 months from present 2.4 mn doses
NeuroRx and Relief Therapeutics have partnered to develop a drug called RLF-100 that has anti-inflammatory and anti-cytokine activity properties.
Around November, IIL had indicated that it was open to discussions with the US major.
SII Chief Executive Officer Adar Poonawalla earlier indicated legal indemnity was required to ensure that the vaccination drive could be completed smoothly
India may start vaccine exports as soon as today
The vaccine manufacturer is making preparations and working on necessary regulatory protocols
Also wait for instructions from the Centre on the second phase of the drive
As for Serum Institute of India's Covishield approval, the drug regulator has mentioned in conditions to be met that the firm has to submit an India-specific risk management plan
Govt unlikely to take a shot at Covid-19 vaccine liability, say legal experts
Quantum of doses to be exported not known
People can't choose between Covishield & Covaxin, says govt; vaccine to take effect two weeks after the second dose
Drug major clarifies it could not present itself before the SEC because of short notice and time zone issues
Serum to supply 11 mn doses at Rs 200 each initially
According to sources, a contract may be signed between the government and the vaccine makers on Monday, and the first batch of vaccinations will be done using Serum Institute's (SII's) Covishield
Write to PM and health minister, call for an independent inquiry
Analysts expect earnings growth to be in the range of 30-40 per cent for drug firms owing to both domestic recovery as well as strong export opportunities
To the media, Somani may be a man of few words but among peers he's known for quick responses
The government is in the final stages of due diligence to ink a supply deal with Serum Institute of India and Bharat Biotech, which have got approval for emergency use of their vaccines